Current Cancer Trials
Participate in One of These Clinical Trials
National Cancer Institute Trials:
With a grant from the National Cancer Institute (NCI), more than 30 established, recognized clinical oncology programs have joined together to form the Northwest Community Oncology Research Program (NW NCORP).
MultiCare Health System is amongst a network of hospitals, clinics, physicians, and researchers working together to provide cancer education and access to new and unique cancer clinical trials to the men, women, and children in communities across Washington, Utah and Alaska.
Visit NW NCORP website for NCI Clinical Trials available at MultiCare
Cancer Clinical Trials offered by MultiCare Health System
Brain
A221101
A Phase III randomized, double-blind placebo-controlled study of Armodafinil (NUVIGIL®) to reduce cancer-related fatigue in patients with high-grade Glioma
Breast - Triple Negative
B-59/GBC 96
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo
NRG BR003
A randomized Phase III trial of adjuvant therapy comparing Doxorubicin plus Cyclophosphamide followed by weekly Paclitaxel with or without Carboplatin for node-positive or high-risk node-negative triple-negative invasive breast cancer
EA1131
A randomized Phase III post-operative trial of platinum-based chemotherapy vs. observation in patients with residual triple-negative basal-like breast cancer following neoadjuvant chemotherapy
S1418/BR006
A randomized Phase III trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor-negative breast cancer with ≥1 cm residual invasive cancer or positive lymph nodes after neoadjuvant chemotherapy
Breast - Node Positive
A011202
A randomized Phase III trial comparing Axillary Lymph Node Dissection to Axillary Radiation in breast cancer patients (cT1-3 N1) who have positive Sentinel Lymph Node Disease after neoadjuvant chemotherapy
NSABP B51
Randomized Phase III clinical trial evaluating post-mastectomy chest wall and regional nodal XRT and post-lumpectomy regional nodal XRT in patients with positive axillary nodes before neoadjuvant chemotherapy who convert to pathologically negative axillary nodes after neoadjuvant chemotherapy
A011502
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Breast - Receptor Positive
B-58 (I3Y-MC-JPCF)
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Breast - ER/PR Positive HER2-Negative
SWOG 1207
Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of Everolimus in patients with high-risk, hormone receptor-positive and HER2-neg breast cancer
Breast - HER2 Positive Metastatic
AFT-38 (PATINA)
A randomized, open-label, Phase III trial to evaluate the efficacy and safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after induction treatment for hormone receptor positive (HR+)/HER2-Postivie metastatic breast cancer
DS8201-A-U301
A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus treatment of investigator’s choice for HER2-positive, unresectable and/or metastatic breast cancer subjects pretreated with prior standard of care HER2 therapies, including T-DM1
DS8201-A-U302
A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane
Breast - Other
A011401
(BWEL) Randomized Phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer
Pancreas
CanStem111P
A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma.
Sequoia AM0010-301
A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Gastrointestinal - Rectal
NRG-GI002
Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Genitourinary - Prostate
TRITON3 CO-338-063
A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency
Genitourinary - Bladder
A031501
A Phase 3 Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation
Gynecologic - Ovarian
GOG 0225
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
Head and Neck
AG013-ODOM-201A (ORAGENICS)
A Phase II, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy
Lung
HS-10296-12-01 (Hansoh)
A Phase 1/2, open-label, multicenter study to evaluate safety, tolerability, pharmacokinetics, and efficacy of oral once-daily administration of HS-10296 in patients with locally advanced or metastatic non-small cell lung cancer who have progressed following prior therapy with an epidermal growth factor receptor Tyrosine Kinase inhibitor agent
Cypress 1 AM0010-201
A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Metastatic Non-Small Cell Lung Cancer whose Tumors Have High PD-L1 Expression (> 50%)
Cypress 2 AM0010-202
An Open-label Randomized Phase 2 Trial of AM0010 in Combination with Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV/Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (0-49%)
R2810-ONC-16111
A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 ≥50%
R2810-ONC-16113
A Randomized, Phase 3, Open-label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 <50%
A081105-EGFR
Randomized, double-blind, placebo-controlled study of Erlotinib or placebo in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer.
SWOG 1400
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Melanoma
EA6134
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
Other (Tumor Profiling, Registries, etc.)
DCP-001
Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
S1417CD
Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer
S1415CD
A Pragmatic Trial to Evaluate a Guideline Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia — Trial Assessing CSF Prescribing Effectiveness and Risk (Tracer).
S1609
DART: Dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors
EAY131
Molecular Analysis for Therapy Choice (MATCH)
PCYC-1134M
A disease registry for patients with Chronic Lymphocytic Leukemia.
PRECISION MED 6504
Collection of blood, urine, and tissue samples from patients with malignant tumors
AFT-28
Direct Oral Anticoagulants (DOACS) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS TRIAL). Arm 1
Pediatric/Adolescent and Young Adult Trials
AALL1131
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-Like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
AAML1331
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
ACNS0831
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
ACNS1422
Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
AEWS1221
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
ANHL12P1
A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)
AHOD1331
Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
